Therapeutic management of Crimean-Congo haemorrhagic fever

Area of Science:

• Infectious Diseases
• Virology
• Public Health

Background:

• Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral illness with a broad geographic distribution, affecting over 30 countries.
• Recent years have seen a notable increase in CCHF incidence, particularly in Europe.
• No specific antiviral treatments are currently proven effective for CCHF.

Purpose of the Study:

• To highlight the critical aspects of managing Crimean-Congo hemorrhagic fever.
• To emphasize the importance of supportive care and biosafety measures in CCHF management.
• To inform clinical practice regarding patient isolation and potential therapeutic interventions.

Main Methods:

• Review of current clinical guidelines and epidemiological data on CCHF.
• Emphasis on laboratory monitoring for key indicators like thrombocytopenia and coagulopathy.
• Discussion of high-level isolation unit requirements and biocontainment procedures.

Main Results:

• CCHF requires intensive supportive treatment due to the lack of specific therapies.
• Laboratory monitoring of thrombocytopenia, coagulopathy, and liver function is vital for patient assessment.
• High-level isolation units are essential to prevent nosocomial transmission.

Conclusions:

• Effective management of CCHF relies on prompt supportive care and stringent biosafety protocols.
• Early consideration of ribavirin may be beneficial in high-risk exposure scenarios.
• Protecting healthcare professionals and preventing disease spread are paramount in CCHF outbreaks.